Additional preclinical studies confirmed the sensitivity of TP53-mutant cells to the combined effects of chemotherapy plus adavosertib[72-74] in non-ovarian cancer models, thus forming the basis for early phase I studies. This evidence concerns the gene TP53 and ovarian carcinoma.